PRKCE and prostate adenocarcinoma: In vitro and in vivo model systems showed that COX-2 is involved in pro-oncogenic kinase PKCε-mediated prostatic adenocarcinoma, and COX-2 inhibitors selectively induced the overexpression of PKCε prostate epithelial cell apoptosis [23].